Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
Ambrx Biopharma PS Ratio: 1776.23 for March 6, 2024
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| March 06, 2024 | 1776.23 |
| March 05, 2024 | 1775.60 |
| March 04, 2024 | 1774.96 |
| March 01, 2024 | 1775.60 |
| February 29, 2024 | 1773.06 |
| February 28, 2024 | 1773.06 |
| February 27, 2024 | 1771.15 |
| February 26, 2024 | 1773.06 |
| February 23, 2024 | 1773.06 |
| February 22, 2024 | 1772.42 |
| February 21, 2024 | 1757.83 |
| February 20, 2024 | 1760.37 |
| February 16, 2024 | 1762.27 |
| February 15, 2024 | 1761.00 |
| February 14, 2024 | 1762.27 |
| February 13, 2024 | 1762.27 |
| February 12, 2024 | 1763.54 |
| February 09, 2024 | 1763.54 |
| February 08, 2024 | 1763.54 |
| February 07, 2024 | 1763.54 |
| February 06, 2024 | 1762.90 |
| February 05, 2024 | 1762.90 |
| February 02, 2024 | 1763.54 |
| February 01, 2024 | 1762.90 |
| January 31, 2024 | 1764.17 |
| Date | Value |
|---|---|
| January 30, 2024 | 1763.54 |
| January 29, 2024 | 1763.54 |
| January 26, 2024 | 1761.64 |
| January 25, 2024 | 1762.27 |
| January 24, 2024 | 1754.65 |
| January 23, 2024 | 1760.37 |
| January 22, 2024 | 1764.17 |
| January 19, 2024 | 1754.65 |
| January 18, 2024 | 1750.85 |
| January 17, 2024 | 1750.85 |
| January 16, 2024 | 1756.56 |
| January 12, 2024 | 1774.96 |
| January 11, 2024 | 1782.58 |
| January 10, 2024 | 1770.52 |
| January 09, 2024 | 1748.31 |
| January 08, 2024 | 1743.23 |
| January 05, 2024 | 864.95 |
| January 04, 2024 | 847.82 |
| January 03, 2024 | 862.41 |
| January 02, 2024 | 859.24 |
| December 29, 2023 | 903.66 |
| December 28, 2023 | 920.16 |
| December 27, 2023 | 932.85 |
| December 26, 2023 | 922.70 |
| December 22, 2023 | 906.20 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
41.88
Minimum
Feb 10 2023
1782.58
Maximum
Jan 11 2024
672.66
Average
605.20
Median
Aug 22 2023
PS Ratio Benchmarks
| Johnson & Johnson | 4.242 |
| Axonics Inc | 8.265 |
| Harpoon Therapeutics Inc (DELISTED) | 2.282 |
| Merck & Co Inc | 3.964 |
| RayzeBio inc (DELISTED) | -- |
PS Ratio Related Metrics
| Price to Book Value | 7.292 |
| Price | 27.99 |
| Earnings Yield | -1.82% |